Citadel Advisors
MSLE

Citadel Advisors’s Satellos Bioscience MSLE Stock Holding History

Citadel Advisors’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$527K Buy
67,738
+25,246
+59% +$173K ﹤0.01% 9743
2026
Q1 		$239K Buy
+42,492
New +$417K ﹤0.01% 11016

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Citadel Advisors's MSLE Position: Q2 2026 in Review

Citadel Advisors increased its Satellos Bioscience (MSLE) stake by 59% in Q2 2026, buying an estimated $173K and bringing the position to 67,738 shares worth $527K. The position accounts for ﹤0.01% of the portfolio, ranked #9743.

Citadel Advisors first reported a position in MSLE in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • Citadel Advisors held 67,738 shares of Satellos Bioscience worth $527K as of Q2 2026.
  • Citadel Advisors bought 25,246 Satellos Bioscience shares in Q2 2026, an estimated $173K.
  • Satellos Bioscience made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #9743 holding.
  • Citadel Advisors first reported a position in Satellos Bioscience in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.